Highlights BioXcel Therapeutics

Equities

BTAI

US09075P1057

Market Closed - Nasdaq Other stock markets 16:00:00 2025-02-07 EST			5-day change	1st Jan Change
0.1650 ^USD	-11.58%		-96.84%	-97.24%

02-06	BioXcel to Implement Reverse Stock Split; Shares Fall	MT
02-05	BioXcel Therapeutics Provides Clinical and Business Update	RE

Highlights

BioXcel Therapeutics Provides Clinical and Business Update	02-05	RE
BioXcel Therapeutics, Inc. Provides Clinical and Business Update	02-05	CI
BofA Securities Downgrades BioXcel Therapeutics to Underperform From Buy, Adjusts Price Target to $0.25 From $7	01-07	MT
Earnings Flash (BTAI) BIOXCEL THERAPEUTICS Reports Q3 Loss $-0.32	11-14	MT
BioXcel Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-14	CI
Bioxcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia	11-12	CI
BioXcel Therapeutics, Inc. and University of North Carolina at Chapel Hill Announce U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder	24-10-15	CI
BioXcel Therapeutics, Inc. Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation	24-09-19	CI
BioXcel Therapeutics, Inc. Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia	24-09-05	CI
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-06	CI
Earnings Flash (BTAI) BIOXCEL THERAPEUTICS Posts Q2 Loss $-0.21 Per Share, vs. Street Est of Loss $-0.69 Per Share	24-08-06	MT
BioXcel Therapeutics Shares Rise After Preliminary Q2 Revenue Exceeds Estimates	24-07-16	MT
BioXcel Therapeutics, Inc. Provides Unaudited Revenue Guidance for the Three Months Ended June 30, 2024	24-07-16	CI
Bioxcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating Prn Treatment of Igalmi? (Dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia	24-06-25	CI
BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-09	CI
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	24-04-22	MT
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	24-04-22	CI
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	24-04-10	CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	24-03-25	MT
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	24-03-15	MT
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	24-03-12	CI
North American Morning Briefing : Inflation Data -2-	24-03-12	DJ
North American Morning Briefing : Nvidia Ignites -2-	24-02-22	DJ
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer	24-02-12	MT
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation	24-02-12	DJ

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioXcel Therapeutics

Equities

BTAI

US09075P1057

Highlights

Filters